Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.34 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10151098 | 0.98 | CYSLTR2 (0.36) | TDP1CYSLTR2CYSLTR1ALDH1A1GLA | |
| SCHEMBL12202626 | 0.98 | CYSLTR2 (0.36) | TDP1CYSLTR2CYSLTR1ALDH1A1GLA | |
| SCHEMBL6742848 | 0.84 | PPARG (0.40) | CYSLTR2CYSLTR1ALDH1A1MEN1KMT2A | |
| SCHEMBL6743535 | 0.83 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1MGLL | |
| SCHEMBL13263804 | 0.83 | CYSLTR2 (0.39) | CYSLTR2CYSLTR1MGLL | |
| SCHEMBL2673173 | 0.83 | CYSLTR2 (0.43) | TDP1CYSLTR2CYSLTR1MGLL | |
| SCHEMBL2673179 | 0.83 | CYSLTR2 (0.43) | TDP1CYSLTR2CYSLTR1MGLL | |
| SCHEMBL2673178 | 0.83 | CYSLTR2 (0.43) | TDP1CYSLTR2CYSLTR1MGLL | |
| SCHEMBL2672423 | 0.80 | PAM (0.39) | TDP1CYSLTR2CYSLTR1MEN1KMT2A | |
| SCHEMBL2672425 | 0.80 | PAM (0.39) | TDP1CYSLTR2CYSLTR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | TDP1 3917/4885CYSLTR2 305/4885CYSLTR1 266/4885 |
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | TDP1 4784/4885CYSLTR2 182/4885CYSLTR1 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.